Suzie,
You are amazing! You were diagnosed less than 2 months ago and you are very, very knowledgeable about this disease. And your posts are very helpful. Thanks, Stan
Forums
-
Stann - Name: Stann
- Who do you know with myeloma?: Myself
- When were you/they diagnosed?: 9/11/09
- Age at diagnosis: 46
Re: Dr. Bradner's research on JQ1
Well Stan, THANK you!
I do my best. I give to others. It makes me happy to do so. My educational background and professional experience has blessed me with the ability to be able to get up to this speed.
The Myeloma Beacon (MB) guided me where to focus, which cut down on the searching and acquisition of knowledge. Even given that some of my inquires are still naive. Overall, though, I gotta tell you the MB is Excellent Cliff Notes!!
The MB added years to my life by simply having data in one place to start the search for more. Without it, I would have spent far more hours/days/weeks searching for clinical trials and outcomes. AND in my case, that would have not been good, as my subset of multiple myeloma is rare and highly aggressive and is seen in less than 5% of newly diagnosed patients.
Ultimately, and most importantly, it lead me to NIH.
I appreciate your positive feedback.
I do my best. I give to others. It makes me happy to do so. My educational background and professional experience has blessed me with the ability to be able to get up to this speed.
The Myeloma Beacon (MB) guided me where to focus, which cut down on the searching and acquisition of knowledge. Even given that some of my inquires are still naive. Overall, though, I gotta tell you the MB is Excellent Cliff Notes!!
The MB added years to my life by simply having data in one place to start the search for more. Without it, I would have spent far more hours/days/weeks searching for clinical trials and outcomes. AND in my case, that would have not been good, as my subset of multiple myeloma is rare and highly aggressive and is seen in less than 5% of newly diagnosed patients.
Ultimately, and most importantly, it lead me to NIH.
I appreciate your positive feedback.
-
suzierose - Name: suzierose
- When were you/they diagnosed?: 2 sept 2011
Re: Dr. Bradner's research on JQ1
In case anyone did not see the update about the latest myeloma "cure", JQ1, here it is.
Contraceptive effect:
"We found that the JQ1 molecule causes a contraceptive effect in males," said Matzuk, also a professor of molecular biology, molecular and human genetics, and pharmacology at BCM. "If you stop the drug, there's complete reversibility."
The research began when Bradner was trying to determine if JQ1 would be valuable as a cancer treatment. He and Matzuk had met earlier when Bradner received a prestigious award from the Burroughs Wellcome Fund. Later Bradner contacted Matzuk about the small molecule. He told Matzuk that he was testing JQ1 as an inhibitor of a member of a family of bromodomain proteins, and he was curious to know whether JQ1 would have an effect on a spermatogenic-specific member of the family called BRDT.
BRDT is involved in the chromatin remodelling process during the generation of sperm in the testis. Chromatin is the combination of DNA and proteins that make up the contents of the nucleus of a cell. It is "remodelled" to give the proteins that regulate how genes act access to the genetic material."
"The research points to a new direction in research in male contraceptives, said Matzuk.
"JQ1 is not the pill for men, because it also binds other members of the bromodomain family," he said. "However, the data is proof of principle that BRDT is an excellent target for male contraception and provides us with useful information for future drug development.""
http://scicasts.com/lifesciences/1874-bioresearch-disease-studies/4703-small-molecule-may-spell-future-for-male-contraceptive
Contraceptive effect:
"We found that the JQ1 molecule causes a contraceptive effect in males," said Matzuk, also a professor of molecular biology, molecular and human genetics, and pharmacology at BCM. "If you stop the drug, there's complete reversibility."
The research began when Bradner was trying to determine if JQ1 would be valuable as a cancer treatment. He and Matzuk had met earlier when Bradner received a prestigious award from the Burroughs Wellcome Fund. Later Bradner contacted Matzuk about the small molecule. He told Matzuk that he was testing JQ1 as an inhibitor of a member of a family of bromodomain proteins, and he was curious to know whether JQ1 would have an effect on a spermatogenic-specific member of the family called BRDT.
BRDT is involved in the chromatin remodelling process during the generation of sperm in the testis. Chromatin is the combination of DNA and proteins that make up the contents of the nucleus of a cell. It is "remodelled" to give the proteins that regulate how genes act access to the genetic material."
"The research points to a new direction in research in male contraceptives, said Matzuk.
"JQ1 is not the pill for men, because it also binds other members of the bromodomain family," he said. "However, the data is proof of principle that BRDT is an excellent target for male contraception and provides us with useful information for future drug development.""
http://scicasts.com/lifesciences/1874-bioresearch-disease-studies/4703-small-molecule-may-spell-future-for-male-contraceptive
-
Mark
Re: Dr. Bradner's research on JQ1
A further update:
This is from this Rockefeller University press release.
Here's the journal article where the research was published:
E Korb et al, "BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice," Nature Neuroscience, Aug 24, 2015 (abstract)
The abstract is fairly technical.
I think these results are yet another example of why it's important not to get overly excited about preclinical (laboratory) research results.
New findings from The Rockefeller University suggest that [JQ1] causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it ...
To test how the drug affected mice’s memories, researchers placed the animals in a box with two objects they’ve never seen before, such as pieces of lego or tiny figurines. Mice typically explore anything unfamiliar, climbing and sniffing around it. After a few minutes, the researchers took the mice out of the box. One day later, they put them back in, this time with one of the objects from the day before and another, unfamiliar one.
Mice that received the placebo drug were much more interested in the new object, presumably because the one from the day before was familiar. But mice treated with Jq1 were equally interested in both objects, suggesting they didn’t remember the previous day’s experience.
This is from this Rockefeller University press release.
Here's the journal article where the research was published:
E Korb et al, "BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice," Nature Neuroscience, Aug 24, 2015 (abstract)
The abstract is fairly technical.
I think these results are yet another example of why it's important not to get overly excited about preclinical (laboratory) research results.
-
JimNY
Re: Dr. Bradner's research on JQ1
Great post, JimNY. I had forgotten about the 2012 "one shot miracle cure" JQ1. I remember how excited patients were about a therapy that had not even put one patient into remission.
-
Mark11
Re: Dr. Bradner's research on JQ1
Thanks, Mark.
In further news on this front, Dr. Bradner, who played an important role in the development of JQ1 and sparked a lot of interest by urging an "open source" approach to cancer drug development, will be joining the pharmaceutical company Novartis as their new head of "drug discovery and early clinical development efforts":
https://www.novartis.com/news/media-releases/novartis-appoints-james-e-bradner-md-president-novartis-institutes-biomedical
In further news on this front, Dr. Bradner, who played an important role in the development of JQ1 and sparked a lot of interest by urging an "open source" approach to cancer drug development, will be joining the pharmaceutical company Novartis as their new head of "drug discovery and early clinical development efforts":
https://www.novartis.com/news/media-releases/novartis-appoints-james-e-bradner-md-president-novartis-institutes-biomedical
-
JimNY
16 posts
• Page 2 of 2 • 1, 2
Return to Treatments & Side Effects